News
BMY
58.06
-0.96%
-0.56
Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist
Barron‘s · 18h ago
Wall Street Lunch: Netflix Draws Bullish Backing As Ad Revenue Seen Doubling To $3B
Seeking Alpha · 21h ago
Replimune Plans Layoffs After FDA Rejects Cancer Therapy. The Stock Hits an All-Time Low.
Barron‘s · 21h ago
Revolution Medicines: PDAC Data Wows Wall Street - Jury's Out On Further Upside
Seeking Alpha · 23h ago
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Seeking Alpha · 23h ago
Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.
Barron‘s · 23h ago
State Street SPDR S&P 500 ETF Trust Experiences Big Inflow
NASDAQ · 1d ago
Dividend stocks to watch: 10 picks as U.S.-Iran tensions shake markets
Seeking Alpha · 1d ago
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
TipRanks · 1d ago
Weekly Report: what happened at BMY last week (0406-0410)?
Weekly Report · 1d ago
Replimune shares extend losses, tumble 56% after FDA rejects melanoma drug RP1
Seeking Alpha · 1d ago
Which Dividend Pharma Stock Should a Value Investor Choose Today?
The Motley Fool · 1d ago
Should BMY’s Camzyos Youth Data and T‑Cell Deal Require Action From Bristol Myers (BMY) Investors?
Simply Wall St · 2d ago
Neuropsychiatric drug developer Seaport files for U.S. IPO
Seeking Alpha · 2d ago
Replimune plans layoffs as FDA rejects cancer drug
Seeking Alpha · 3d ago
Potential $5,000 Monthly Income: 12 Investments To Buy And Hold For The Next 10 Years
Seeking Alpha · 3d ago
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
NASDAQ · 3d ago
FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short
Benzinga · 3d ago
Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second Time
Barron‘s · 3d ago
Replimune under pressure as FDA rejects lead asset again
Seeking Alpha · 4d ago
More
Webull provides a variety of real-time BMY stock news. You can receive the latest news about Bristol-Myers Squibb Co through multiple platforms. This information may help you make smarter investment decisions.
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.